# Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Study · id `cardio:ct-nct07268586` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07268586](<https://clinicaltrials.gov/study/NCT07268586>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07268586

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.

## Technical summary

Registry record NCT07268586. Randomized; triple masking; primary purpose prevention. Start 2025-08-01 (actual); primary completion 2026-02-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 158 participants (enrolled count; ClinicalTrials.gov record NCT07268586, source copy `cardio:ctgov-nct07268586-2026-03-10`, retrieved 2026-10-26)
- Started: 2025-08-01 (actual) (ClinicalTrials.gov record NCT07268586, source copy `cardio:ctgov-nct07268586-2026-03-10`, retrieved 2026-10-26)
- Primary completion: 2026-02-28 (actual) (ClinicalTrials.gov record NCT07268586, source copy `cardio:ctgov-nct07268586-2026-03-10`, retrieved 2026-10-26)
- Completion: 2026-02-28 (actual) (ClinicalTrials.gov record NCT07268586, source copy `cardio:ctgov-nct07268586-2026-03-10`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07268586, source copy `cardio:ctgov-nct07268586-2026-03-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07268586-2026-03-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- Condition: Myocardial Infarction
- Intervention (Drug): Intravenous atropine immediately before wire crossing during primary percutaneous coronary intervention
- Intervention (Drug): Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention
- Lead sponsor: Ain Shams University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Ain Shams University (`cardio:org-ain-shams-university`)

## Provenance

Content hash: b47c202ec169058148a09145da9707ba7874dfceff7c6ec3787e35bd2306ca78
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
